Primary biliary cholangitis
Autoimmune destruction of intrahepatic bile ducts (anti-mitochondrial antibody)
Overview
A chronic autoimmune cholestatic liver disease - immune destruction of the small intrahepatic bile ducts leading to cholestasis, fibrosis and cirrhosis. Classically a middle-aged WOMAN with FATIGUE and ITCH (pruritus); cholestatic LFTs with a positive ANTI-MITOCHONDRIAL ANTIBODY (AMA). Treated with ursodeoxycholic acid. Associated with other autoimmune disease (Sjogren, thyroid).
Recognise
- Middle-aged woman with FATIGUE and PRURITUS (often the earliest/most prominent), later jaundice
- Cholestatic LFTs (raised ALP/GGT), raised IgM; xanthelasma, hepatomegaly; complications of cholestasis (osteoporosis, fat-soluble vitamin deficiency)
- Associations: Sjogren, autoimmune thyroid, coeliac, scleroderma/CREST
Red flags
- Progression to cirrhosis/portal hypertension; HCC risk
- Severe pruritus impairing quality of life
Differentials & how to tell them apart
Investigations
Cholestatic LFTs (ALP up), ANTI-MITOCHONDRIAL ANTIBODY (AMA - the hallmark, ~95%), raised IgM; USS/MRCP (exclude obstruction/PSC); biopsy if needed.
Management
Ursodeoxycholic acid (+ cholestyramine for itch)
- 1Confirm cholestatic LFTs + AMA (+/- biopsy). Ursodeoxycholic acid to slow progression; cholestyramine for pruritus; bone protection and fat-soluble vitamins.Gate: Itch in cholestasis is treated with cholestyramine (bile-acid sequestrant), NOT antihistamines; distinguish from PSC (men/UC/beaded ducts) and autoimmune hepatitis (hepatitic/ANA-IgG)
- 2Obeticholic acid for inadequate response; manage cirrhosis/portal hypertension; transplant for end-stage disease.
Key points
Middle-aged woman + fatigue + itch + cholestatic LFTs + AMA + raised IgM = PBC, treat with ursodeoxycholic acid. Cholestyramine (not antihistamines) for the itch. PSC is the men/UC/beaded-duct counterpart.
Monitor & prognosis
LFTs; bone density; cirrhosis surveillance.
Slowed by ursodeoxycholic acid; cirrhosis if advanced.
Source: EASL; BSG